Anterios Therapeutics

📍 New York, United States🗓 Founded 2002👥 1 employees💰 Last funded 2014
Biotechnology Research🌐 allergan.com
Website LinkedIn
Anterios is a privately held, clinical-stage biopharmaceutical company that is developing next-generation botulinum-based prescription products for medical dermatology and aesthetic medicine. Anterios has developed NDS, a proprietary platform technology that enables local, targeted delivery of botulinum toxin and other macromolecules across the skin without needles or other invasive treatments that can be destructive to the skin. NDS also enables the formulation of macromolecules as ready-to-use liquid injectable products. In the future, Anterios plans to develop additional dermatology products to topically deliver active ingredients other than botulinum, as well as formulate additional injectable products that require deeper delivery. I
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2002
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Anterios Therapeutics?
Anterios Therapeutics has 1 investors on record on gritt.io.
When did Anterios Therapeutics last raise funding?
The most recent investment in Anterios Therapeutics recorded on gritt.io was in 2014.
When was Anterios Therapeutics founded?
Anterios Therapeutics was founded in 2002.
What industry is Anterios Therapeutics in?
Anterios Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Anterios Therapeutics based?
Anterios Therapeutics is headquartered in New York, United States.